Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blinded, Randomized, Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients

NCT01576419 is registered in ClinicalTrials.gov with PMG Pharm Co., Ltd as lead sponsor.

NCT NCT01576419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01576419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blinded, Randomized, Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients
Lead sponsor
PMG Pharm Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
September 30, 2011
Enrollment
309 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee